Key Financial Data Of Group

Astellas Pharma Inc. - Filing #7551605

Concept As at
2023-06-30
2023-04-01 to
2023-06-30
As at
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2022-06-30
As at
2022-06-30
Key financial data of group
Business results of group
Cash and cash equivalents
561,487,000,000 JPY
376,840,000,000 JPY
313,013,000,000 JPY
Revenue
374,990,000,000 JPY
1,518,619,000,000 JPY
381,791,000,000 JPY
Profit (loss) before tax
46,850,000,000 JPY
132,361,000,000 JPY
31,679,000,000 JPY
Profit (loss), attributable to owners of parent
33,129,000,000 JPY
98,714,000,000 JPY
24,812,000,000 JPY
Comprehensive income, attributable to owners of parent
134,507,000,000 JPY
205,277,000,000 JPY
134,396,000,000 JPY
Equity attributable to owners of parent
1,578,417,000,000 JPY
1,507,954,000,000 JPY
1,539,052,000,000 JPY
Total assets
2,797,958,000,000 JPY
2,456,518,000,000 JPY
2,481,843,000,000 JPY
Basic earnings (loss) per share
18.46
54.24
13.59
Diluted earnings (loss) per share
18.42
54.09
13.59
Ratio of owners' equity to gross assets
0.564 xbrli:pure
0.614 xbrli:pure
0.620 xbrli:pure
Cash flows from (used in) operating activities
12,198,000,000 JPY
327,767,000,000 JPY
48,832,000,000 JPY
Cash flows from (used in) investing activities
-12,300,000,000 JPY
-84,500,000,000 JPY
-19,144,000,000 JPY
Cash flows from (used in) financing activities
165,041,000,000 JPY
-195,623,000,000 JPY
-46,602,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.